These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 1715103)

  • 1. Ratio of polyclonal-monoclonal prostate-specific antigen levels. Discrimination of nodal status in prostate tumors that produce low marker levels.
    Stephenson RA; Greskovich FJ; Fritsche HA; James BC
    Urol Clin North Am; 1991 Aug; 18(3):467-71. PubMed ID: 1715103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer-associated markers.
    Chu TM
    Immunol Ser; 1990; 53():339-56. PubMed ID: 1713065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients.
    Horoszewicz JS; Kawinski E; Murphy GP
    Anticancer Res; 1987; 7(5B):927-35. PubMed ID: 2449118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical demonstration of prostate-specific antigen in metastases with the use of monoclonal antibody F5.
    Papsidero LD; Croghan GA; Asirwatham J; Gaeta J; Abenoza P; Englander L; Valenzuela L
    Am J Pathol; 1985 Dec; 121(3):451-4. PubMed ID: 2416221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Analysis of the serum concentration of prostate-specific antigen as a biological marker in the evolution of disseminated prostatic cancer].
    Morote Robles J; de Torres Mateos JA; Soler-Roselló A
    Actas Urol Esp; 1988; 12(2):152-7. PubMed ID: 2458015
    [No Abstract]   [Full Text] [Related]  

  • 6. [Clinical evaluation of a prostate-specific antigen as a serum marker of prostatic cancer].
    Park YC; Kiwamoto H; Nishioka T; Tsujihashi H; Mitsubayashi S; Matsuura T; Akiyama T; Kurita T; Miyamoto T
    Hinyokika Kiyo; 1987 Jun; 33(6):883-8. PubMed ID: 2445188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum prostatic acid phosphatase activity and prostate specific antigen when the prostate gland is enlarged.
    Jenkins D; Jones RT; Clarke AM
    Med Lab Sci; 1991 Apr; 48(2):161-3. PubMed ID: 1719330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
    Stamey TA; Ekman PE; Blankenstein MA; Cooper EH; Kontturi M; Lilja H; Oesterling JE; Stenman UH; Turkes A
    Scand J Urol Nephrol Suppl; 1994; 162():73-87; discussion 115-27. PubMed ID: 7529430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunologic markers and the diagnosis of prostatic cancer.
    Ban Y; Wang MC; Chu TM
    Urol Clin North Am; 1984 May; 11(2):269-76. PubMed ID: 6203206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of cell proliferation marker (TPS), natural killer (NK) activity and tumor load serotest (PSA) in untreated and treated prostatic tumors.
    Tarle M; Kovacić K; Kastelan M
    Anticancer Res; 1993; 13(1):215-8. PubMed ID: 7682800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prostate-specific antigen as a prognostic parameter of treated prostate carcinoma--a reliable tumor marker?].
    Knönagel H; Gautschi K; Vonderschmitt DJ; Hauri D
    Helv Chir Acta; 1988 Jul; 55(3):333-5. PubMed ID: 2459081
    [No Abstract]   [Full Text] [Related]  

  • 12. Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer.
    Miyata Y; Sakai H; Hayashi T; Kanetake H
    Prostate; 2003 Feb; 54(2):125-32. PubMed ID: 12497585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prostatic acid phosphatase (PAP), gamma-seminoprotein (gamma-Sm) and prostate specific antigen (PA) in prostatic cancer].
    Akimoto S; Akakura K; Shimazaki J
    Hinyokika Kiyo; 1988 Aug; 34(8):1389-96. PubMed ID: 2461644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-comparison of PSA and PAP values in a wide spectrum of prostate cancer conditions.
    Tarle M
    Anticancer Res; 1988; 8(4):569-72. PubMed ID: 2460018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The significance of serum prostate-specific antigen, gamma-seminoprotein and prostatic acid phosphatase as prostate cancer markers].
    Yamaguchi K; Tanaka M; Kitagawa N; Kotake T; Yanagi S; Ito H
    Hinyokika Kiyo; 1989 Jun; 35(6):987-91. PubMed ID: 2478006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostatic intraepithelial neoplasia and prostate-specific antigen.
    Brawer MK
    Urology; 1989 Dec; 34(6 Suppl):62-5. PubMed ID: 2481364
    [No Abstract]   [Full Text] [Related]  

  • 17. [Enzyme-linked immunosorbent assay for serum prostate specific antigen (PSA) using monoclonal antibodies].
    Setoguchi C; Matsumoto K; Samori T; Kimura E; Harukaze S
    Rinsho Byori; 1998 Jan; 46(1):79-82. PubMed ID: 9492543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value of prostate-specific antigen in the management of localized prostatic cancer.
    Walsh PC; Oesterling JE; Epstein JI; Bruzek DJ; Rock RC; Chan DW
    Prog Clin Biol Res; 1989; 303():27-33. PubMed ID: 2476820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostatic intraepithelial neoplasia: significance and correlation with prostate-specific antigen and transrectal ultrasound. Proceedings of a workshop of the National Prostate Cancer Detection Project. March 13, 1989, Bethesda, Maryland.
    Urology; 1989 Dec; 34(6 Suppl):2-69. PubMed ID: 2481359
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunocytochemical evaluation of human prostatic carcinomas for carcinoembryonic antigen, nonspecific cross-reacting antigen, beta-chorionic gonadotrophin, and prostate-specific antigen.
    Purnell DM; Heatfield BM; Trump BF
    Cancer Res; 1984 Jan; 44(1):285-92. PubMed ID: 6197163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.